Li Shan, Huang Huanhuan, Shi Haoning, Chen Zhiyu, Jiang Siqi, Yu Xinyu, Ren Keke, Huang Qi, Zhao Qinghua
Department of Nursing, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Innov Aging. 2025 Jun 20;9(7):igaf065. doi: 10.1093/geroni/igaf065. eCollection 2025 Jul.
The complex interplay between diet, gut microbiota, and metabolic health has gained increasing recognition as a key factor in the development of obesity and related conditions, such as sarcopenia. This study examines the relationship between the dietary index for gut microbiota (DI-GM) and sarcopenia, while exploring the potential mediating role of the body roundness index (BRI) in this association. By integrating these factors, our findings aim to shed light on the diet-gut microbiota-sarcopenia interaction and its implications for personalized dietary interventions.
Data were obtained from the National Health and Nutrition Examination Survey (NHANES) 2011-2018. Multivariable weighted regression analyses were conducted to assess the association between DI-GM and sarcopenia. Restricted cubic spline analyses were used to evaluate potential non-linear relationships. Additionally, mediation analysis was performed to determine whether the BRI mediated the relationship between DI-GM and sarcopenia.
A total of 10,190 participants were included in the study, of whom 7.57% were diagnosed with sarcopenia. In the weighted linear regression analysis, each one-point increase in DI-GM was associated with a 12% reduction in the prevalence of sarcopenia (OR = 0.88, 95% CI: 0.82, 0.95). Specifically, a higher beneficial gut microbiota score was significantly associated with a lower prevalence of sarcopenia (OR = 0.82, 95% CI: 0.75, 0.89). Mediation analysis revealed that BRI accounted for 23% of the total effect of DI-GM on sarcopenia. Among the beneficial components, those with a significant mediation effect contributed approximately 9% of the total effect.
The DI-GM was found to be negatively associated with the prevalence of sarcopenia, with BRI playing a crucial mediating role. These findings highlight the importance of the diet-gut microbiota-sarcopenia interaction and underscore the potential for incorporating dietary and microbiota-targeted interventions in personalized therapeutic strategies for sarcopenia.
饮食、肠道微生物群和代谢健康之间复杂的相互作用，作为肥胖及相关病症（如肌肉减少症）发展的关键因素，已得到越来越多的认可。本研究探讨肠道微生物群饮食指数（DI-GM）与肌肉减少症之间的关系，同时探究身体圆润度指数（BRI）在这种关联中的潜在中介作用。通过整合这些因素，我们的研究结果旨在阐明饮食-肠道微生物群-肌肉减少症之间的相互作用及其对个性化饮食干预的意义。
数据来自2011 - 2018年美国国家健康与营养检查调查（NHANES）。进行多变量加权回归分析，以评估DI-GM与肌肉减少症之间的关联。使用受限立方样条分析来评估潜在的非线性关系。此外，进行中介分析以确定BRI是否介导了DI-GM与肌肉减少症之间的关系。
本研究共纳入10190名参与者，其中7.57%被诊断为肌肉减少症。在加权线性回归分析中，DI-GM每增加1分，肌肉减少症患病率降低12%（OR = 0.88，95% CI：0.82，0.95）。具体而言，较高的有益肠道微生物群评分与较低的肌肉减少症患病率显著相关（OR = 0.82，95% CI：0.75，0.89）。中介分析显示，BRI占DI-GM对肌肉减少症总效应的23%。在有益成分中，具有显著中介作用的成分约占总效应的9%。
发现DI-GM与肌肉减少症患病率呈负相关，BRI起关键中介作用。这些发现凸显了饮食-肠道微生物群-肌肉减少症相互作用的重要性，并强调了在肌肉减少症个性化治疗策略中纳入饮食和微生物群靶向干预措施的潜力。
